Literature DB >> 8356077

Molecular regulation of human interleukin 2 and T-cell function by interleukin 4.

E M Schwarz1, P Salgame, B R Bloom.   

Abstract

Distinct functional T-cell subsets, differing in the patterns of lymphokines produced, regulate cell-mediated and humoral immune responses. The two major types and their principal products, interleukin 4 and interferon gamma (IL-4 and IFN-gamma), are reciprocally negatively interactive. To analyze the molecular mechanism of IL-4-mediated suppression of cell-mediated immunity we studied its effects on expression of interleukin 2 (IL-2) and IFN-gamma. IL-4 pretreatment of Jurkat cells prior to stimulation resulted in a decrease in transcription of the IL2 gene. IL-4 suppressed IL-2 and IFN-gamma mRNA levels in primary human T cells, and addition of anti-CD28 antibodies relieved this suppression. Using enhancer-reporter constructs, IL-4 specifically down-regulated the NFIL-2B element. Electrophoretic mobility shift assays using a DNA oligomer containing the NFIL-2B binding site indicated that IL-4 inhibited the NFIL-2B complex and that the NFIL-2B DNA binding factor is distinct from AP-1. These results suggest that IL-4 may regulate development and function of T-cell subsets involved in cell-mediated immunity in part by inhibiting factors required for transcription of the IL2 gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8356077      PMCID: PMC47217          DOI: 10.1073/pnas.90.16.7734

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  The regulation of transcription by phosphorylation.

Authors:  T Hunter; M Karin
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

2.  Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones.

Authors:  P Salgame; J S Abrams; C Clayberger; H Goldstein; J Convit; R L Modlin; B R Bloom
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

3.  Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28.

Authors:  J D Fraser; B A Irving; G R Crabtree; A Weiss
Journal:  Science       Date:  1991-01-18       Impact factor: 47.728

4.  Nuclear factor of activated T cells contains Fos and Jun.

Authors:  J Jain; P G McCaffrey; V E Valge-Archer; A Rao
Journal:  Nature       Date:  1992-04-30       Impact factor: 49.962

5.  Analysis of the AP-1 sites in the IL-2 promoter.

Authors:  J Jain; V E Valge-Archer; A Rao
Journal:  J Immunol       Date:  1992-02-15       Impact factor: 5.422

6.  The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes.

Authors:  P S Mattila; K S Ullman; S Fiering; E A Emmel; M McCutcheon; G R Crabtree; L A Herzenberg
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

7.  Differential induction of transcription factors that regulate the interleukin 2 gene during anergy induction and restimulation.

Authors:  C Go; J Miller
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

8.  Negative regulation of interleukin 2 transcription by the glucocorticoid receptor.

Authors:  J P Northrop; G R Crabtree; P S Mattila
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

9.  Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements.

Authors:  A Vacca; M P Felli; A R Farina; S Martinotti; M Maroder; I Screpanti; D Meco; E Petrangeli; L Frati; A Gulino
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

10.  The AP-1 site at -150 bp, but not the NF-kappa B site, is likely to represent the major target of protein kinase C in the interleukin 2 promoter.

Authors:  J Jain; V E Valge-Archer; A J Sinskey; A Rao
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

View more
  6 in total

1.  Analysis of orbital T cells in thyroid-associated ophthalmopathy.

Authors:  G Förster; E Otto; C Hansen; K Ochs; G Kahaly
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

2.  Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR).

Authors:  M Niessner; B A Volk
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

3.  Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo.

Authors:  D P Sharma; A J Ramsay; D J Maguire; M S Rolph; I A Ramshaw
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

4.  Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-alpha in cultured endothelial cells.

Authors:  M F Iademarco; J L Barks; D C Dean
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

5.  A labile transcriptional repressor modulates endotoxin tolerance.

Authors:  K E LaRue; C E McCall
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

6.  Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.

Authors:  Chia-Sing Lu; Ching-Wen Lin; Ya-Hsuan Chang; Hsuan-Yu Chen; Wei-Chia Chung; Wei-Yun Lai; Chao-Chi Ho; Tong-Hong Wang; Chi-Yuan Chen; Chen-Lin Yeh; Sean Wu; Shu-Ping Wang; Pan-Chyr Yang
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.